The AI revolution is swiftly advancing beyond digital realms into tangible innovations, boosting infrastructure from chips to data centers. At the 2026 World Economic Forum, Nvidia’s Jensen Huang framed AI as a five-layer system: energy, chips, cloud, models, and applications, where the final layer delivers real-world impact. Among all fields, medicine stands out for its potential to turn AI-driven capacity into profound economic and social value.
In 2024, the U.S. spent $5.3 trillion on healthcare, including substantial investment in prescription drugs, highlighting the immense resources directed towards disease treatment. Medicines that significantly alter widespread diseases can enhance lives, reduce healthcare burdens, and provide lucrative returns for developers and investors. The blockbuster success of drugs like Eli Lilly’s tirzepatide, with $36.5 billion in combined annual sales, illustrates this scale.
AI promises to transform drug discovery by helping scientists navigate complex decisions, rank promising paths, and design smarter experiments based on large data analysis. Despite challenges like complex biology and uneven data quality, the most impactful AI systems integrate continuous learning loops from experiments, accelerating innovation and improving drug candidates’ chances.
Though clinical proof remains limited, progress in areas such as AI for mass spectrometry has already sped up drug discovery timelines, uncovering new therapeutic prospects. The key measure of AI’s success will be its ability to enhance real-world clinical outcomes, not just laboratory results.
For stakeholders, the critical question is whether AI can improve decision-making throughout drug development, leading to better trial results and patient benefits. The hope is that AI-driven breakthroughs will emerge more frequently, bringing millions healthier years and renewed hope sooner than ever before.
Authors: Viswa Colluru, CEO of Enveda, and Bigyan Bista, Head of Capital Formation at Enveda.
